MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
Frequently asked questions
What sector does MAIA Biotechnology Inc. (MAIA) operate in?
MAIA Biotechnology Inc. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is MAIA Biotechnology Inc. (MAIA) current stock price?
As of the latest data, MAIA Biotechnology Inc. stock price is $1.11, with a previous close of $1.15. MAIA Biotechnology Inc. lost -$0.04 in the last trading session, representing a -3.48% loss.
What is MAIA Biotechnology Inc. (MAIA) current market capitalization?
MAIA Biotechnology Inc. market cap is approximately 68.53 million.
What is MAIA Biotechnology Inc. (MAIA) Earnings Per Share (EPS)?
The trailing EPS is -$0.62, and the forward EPS is $1.11.
What is MAIA Biotechnology Inc. (MAIA) EBITDA?
MAIA Biotechnology Inc. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -7.57 million.
Does MAIA Biotechnology Inc. (MAIA) pay dividends?
No. MAIA Biotechnology Inc. does not pay a dividend.
When is MAIA Biotechnology Inc. (MAIA) next earnings report?
MAIA Biotechnology Inc. is expected to release its next earnings report on September 30, 2026.
What is MAIA Biotechnology Inc. (MAIA) beta (volatility) score?
MAIA Biotechnology Inc. has a beta of 0.281, indicating lower volatility than the overall market.